AstraZeneca's drug Fasenra flops in COPD trial

LONDON (Reuters) - AstraZeneca's said its first respiratory biologic medicine Fasenra failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Publication date: Available online 20 May 2019Source: Life SciencesAuthor(s): Pengbo Sun, Ruin Ye, Cuihong Wang, Shuang Bai, Li ZhaoAbstractAimsAcute exacerbation is a major event that alters the natural course of chronic obstructive pulmonary disease (COPD), and recurrent exacerbation results in worse clinical outcomes and greater economic consequences. While some patients suffer frequent exacerbations, others experience no exacerbations; this study was designed to detect proteins that were differentially abundant in COPD frequent exacerbators and assess whether those expression profiles are unique among COPD patients.Mai...
Source: Life Sciences - Category: Biology Source Type: research
Condition:   Chronic Obstructive Pulmonary Disease Intervention:   Drug: N-acetylcysteine Sponsor:   Siriraj Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Obstructive Pulmonary Disease Intervention:   Diagnostic Test: Structured self-monitoring during an altitude ascent and stay at high altitude Sponsors:   University of Zurich;   National Center of Cardiology and Internal Medicine, Kyrgyzstan Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Other: Modified American Thoracic Society and National Heart and Lung Institute-Division of Lung Disease Respiratory (Mod. ATS-DLD-078);   Other: Modified Medical Research Council (mMRC) Dyspnea Scale;   Other: Exacerbations of Chronic Pulmonary Disease Tool (EXACT);   Other: COPD Assessmen t Test (CAT);   Other: Evaluating Respiratory Symptoms in COPD (E-RS: COPD);   Other: Telephonic interviews;   Other: Electronic Diary (eDiary);   Diagnostic T...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Might the risk of acute COPD exacerbations differ between biomass smoke and tobacco smoke exposure? In what ways?BMC Pulmonary Medicine
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine Journal Article Source Type: news
Publication date: Available online 19 May 2019Source: Life SciencesAuthor(s): Md. Samsuzzaman, Md. Sahab Uddin, Muhammad Ajmal Shah, Bijo MathewAbstractAirway mucin overproduction is the hallmark risk factor of asthma, which is associated with the reduction of lung function. An aberrant mucin expression is responsible for airway obstruction due to its high viscous characteristics. Among the mucins discovered, MUC5AC is the prime mucin of airway epithelia. Nowadays, mucins induced asthma and chronic obstructive pulmonary disease (COPD) are a great concern all over the world. This review focuses on the effects of natural com...
Source: Life Sciences - Category: Biology Source Type: research
The device is being trialled on NHS patients with asthma and chronic obstructive pulmonary disease (COPD), a group of lung conditions including emphysema and chronic bronchitis.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
CONCLUSION: To our knowledge this is the first study comparing the levels of protein and mRNA in the serum material of HGF, c-MET, EGF and EGFR parameters in lung cancer patients' blood samples. Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of these biomarkers role for guiding us to sellect individualized itargeted therapies. PMID: 31104010 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Condition:   Chronic Obstructive Pulmonary Disease Interventions:   Combination Product: High-flow oxygen therapy (HFOT);   Combination Product: Low-flow oxygen therapy (LFOT) Sponsors:   University of Zurich;   National Center of Cardiology and Internal Medicine, Kyrgyzstan Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The Clinical Respiratory Journal, EarlyView.
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: LETTER TO THE EDITOR Source Type: research
More News: AstraZeneca | Chronic Obstructive Pulmonary | Clinical Trials | Health | Respiratory Medicine